Tran B. Nguyen serves as the Chief Strategy Officer and Chief Financial Officer at Prothena Corporation plc, a clinical-stage neuroscience company focused on developing novel therapies for neurodegenerative and rare peripheral amyloid diseases. In her dual role, Nguyen is responsible for overseeing the company's financial operations, strategic planning, and corporate development. Her leadership has been instrumental in guiding Prothena through various stages of growth and development, including advancing its pipeline of potential treatments. Before joining Prothena, Nguyen amassed a wealth of experience in the biotechnology and pharmaceutical industries. She previously held the position of Chief Financial Officer at Tetraphase Pharmaceuticals, where she played a key role in the company's successful IPO and subsequent financings. Prior to Tetraphase, Nguyen served in senior financial roles at several other biotech firms, including Momenta Pharmaceuticals and Genzyme Corporation. Her extensive background in finance and strategic planning has equipped her with the skills necessary to drive Prothena's mission of delivering life-changing therapies to patients. Nguyen's contributions to Prothena extend beyond her financial and strategic expertise. She has been a driving force in fostering a culture of innovation and collaboration within the company. Under her leadership, Prothena has strengthened its position as a leader in the field of neuroscience, securing partnerships with major pharmaceutical companies and advancing its clinical programs. Nguyen's dedication to the company's mission and her ability to navigate the complex landscape of drug development have made her an invaluable asset to Prothena and its stakeholders.